A living cell therapy can change its number, location and state after administration. The starting dose, a sampled cell count and useful function are different measurements.
After a cell infusion, measured abundance depends on division, survival and redistribution. In vivo engineering may also continue to generate newly engineered cells. A blood sample describes one compartment and time; it cannot count all cells in the body or establish entry into a tumor. Detectable receptor-encoding sequences, viable receptor-positive cells, persistent markers and functional activity should be reported separately.
Shares Armoured, logic-gated & next-gen CARs, CAR-NK & CAR-macrophage, In vivo CAR-T, TIL therapy.
Shares Armoured, logic-gated & next-gen CARs, CAR-NK & CAR-macrophage, TCR-T cell therapy, CAR-T cell therapy.
Shares Ex vivo cell expansion, NK cell therapy and CAR-NK, TIL therapy, TCR-T cell therapy.
Shares Cell-therapy safety switches, Armoured, logic-gated & next-gen CARs, CAR-T cell therapy.
Shares Logic-gated therapeutics (AND, NOT gates), T-cell exhaustion and CAR-T persistence, T-cell engagers (bispecific), CAR-T cell therapy.
Shares TIL therapy, TCR-T cell therapy, CAR-T cell therapy.
Shares NK cell therapy and CAR-NK, CAR-NK & CAR-macrophage, TIL therapy, TCR-T cell therapy.
Shares Armoured, logic-gated & next-gen CARs, In vivo CAR-T, CAR-T cell therapy.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/